Alcohol Monitor Validation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03617705 |
|
Recruitment Status :
Recruiting
First Posted : August 6, 2018
Last Update Posted : August 17, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Human Immunodeficiency Virus (HIV) | Device: Skyn Monitor Lab Session 1 Device: Skyn Monitor Field Test with EMA App Device: Skyn Monitor Lab Session 2 | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Other |
| Official Title: | Laboratory and Field Validation of a Wrist-Worn Alcohol Monitor |
| Actual Study Start Date : | April 1, 2019 |
| Estimated Primary Completion Date : | June 30, 2022 |
| Estimated Study Completion Date : | June 30, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: HIV+ drinkers
Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
|
Device: Skyn Monitor Lab Session 1
Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
Other Names:
Device: Skyn Monitor Field Test with EMA App After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
Other Names:
Device: Skyn Monitor Lab Session 2 Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
Other Names:
|
|
Active Comparator: HIV- drinkers
Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
|
Device: Skyn Monitor Lab Session 1
Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
Other Names:
Device: Skyn Monitor Field Test with EMA App After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
Other Names:
Device: Skyn Monitor Lab Session 2 Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
Other Names:
|
- Transdermal alcohol concentration [ Time Frame: 2 weeks ]Assess the validity of the Skyn monitor through comparison with laboratory grade breathalyzer in two fixed-dose lab alcohol administration sessions. The threshold of detection will be defined as the consumption level with a 60% or higher detection rate. Rate of successful detection at the end of 1 beer, 2 beers, and 3 beers will be calculated respectively. This will be done by observing the data series and curves from the monitor readings. Successful detection of consumed alcohol is defined by a TAC peak (e.g., ≥.02g/dL) with a reasonably visible elevation slope for absorption (i.e., TAC curve goes up at a reasonable pace) and a declination slope for elimination (i.e., TAC curve goes down at the reasonable pace).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 21 Years to 64 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- HIV+ consumers of alcohol; self-reported ≥ 5 days with at least 1 alcoholic drink, and ≥1days with at least 3 drinks
- HIV- consumers of alcohol; self-reported ≥ 5 days with at least 1 alcoholic drink, and ≥1days with at least 3 drinks
Exclusion Criteria:
- non-drinkers
- recent addiction treatment or treatment seeking
- urine positive for illegal drugs except THC (not applicable to those who are only invited to do field test);
- past & current alcohol withdrawal
- severe alcohol use disorder (DSM-5)
- meeting criteria for current nicotine dependence (not applicable to field only participants) or current substance use disorder (excluding mild cannabis use disorder and mild/moderate alcohol use disorder)
- medical conditions (other than HIV) contraindicating alcohol
- pregnancy/breastfeeding in women
- psychosis or other severe psychiatric conditions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03617705
| Contact: Yan Wang, PhD | 352-294-5942 | ywang48@ufl.edu |
| United States, Florida | |
| HealthStreet | Recruiting |
| Gainesville, Florida, United States, 32608 | |
| University of Florida | Recruiting |
| Gainesville, Florida, United States, 32611 | |
| Principal Investigator: | Yan Wang, PhD | University of Florida |
| Responsible Party: | University of Florida |
| ClinicalTrials.gov Identifier: | NCT03617705 |
| Other Study ID Numbers: |
IRB201801188-N 1R21AA027191-01 ( U.S. NIH Grant/Contract ) 5R21AA027191-02 ( U.S. NIH Grant/Contract ) |
| First Posted: | August 6, 2018 Key Record Dates |
| Last Update Posted: | August 17, 2021 |
| Last Verified: | August 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Product Manufactured in and Exported from the U.S.: | Yes |
|
alcohol consumption |
|
Acquired Immunodeficiency Syndrome HIV Infections Immunologic Deficiency Syndromes Immune System Diseases Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Lentivirus Infections |
Retroviridae Infections RNA Virus Infections Virus Diseases Slow Virus Diseases Ethanol Anti-Infective Agents, Local Anti-Infective Agents Central Nervous System Depressants Physiological Effects of Drugs |

